Literature DB >> 25971681

Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression.

Pu-xiang Chen1, Qiao-yan Li, Zhulin Yang.   

Abstract

The presence of cancer stem-like cells (CSCs) has been demonstrated to be associated with tumor metastasis, chemoresistance, and rapid recurrence of various tumors. The impact of CSC-related markers in the metastasis and prognosis of ovarian cancer has not been well established. In this study, the protein expression of musashi-1 and ALDH1 was measured using immunohistochemistry. Results demonstrated that the percentage of positive musashi-1 and ALDH1 expression were significantly higher in ovarian serous adenocarcinomas, mucinous adenocarcinomas and clear cell adenocarcinomas than in cystadenomas and normal tissues. The percentage of positive musashi-1 and ALDH1 expression were significantly lower in patients identified with clinical stage I or II ovarian adenocarcinomas without lymph node metastasis compared to patients with clinical stage III or IV tumors and lymph node metastasis. The expression of musashi-1 and ALDH1 was found to be highly consistent in ovarian adenocarcinomas. Univariate Kaplan-Meier analysis showed a negative correlation between musashi-1 or ALDH1 expression and overall survival. Multivariate Cox regression analysis showed that positive expression of musashi-1 or ALDH1 in ovarian adenocarcinoma was an independent predictor of poor prognosis. Our study suggested that musashi-1 and ALDH1 expression are closely related to metastasis of ovarian adenocarcinoma. The positive expression of musashi-1 and ALDH1 might be a poor-prognostic factor of ovarian adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25971681     DOI: 10.1007/s12253-015-9943-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  32 in total

1.  Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.

Authors:  Norman E Sládek; Rahn Kollander; Lakshmaiah Sreerama; David T Kiang
Journal:  Cancer Chemother Pharmacol       Date:  2002-02-13       Impact factor: 3.333

2.  Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.

Authors:  Mohamed Kamel Hassan; Hidemichi Watari; Lane Christenson; Saverio Bettuzzi; Noriaki Sakuragi
Journal:  Tumour Biol       Date:  2011-07-15

Review 3.  Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose?

Authors:  Malcolm R Alison; Naomi J Guppy; Susan M L Lim; Linda J Nicholson
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

4.  Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.

Authors:  Shan Deng; Xiaojun Yang; Heini Lassus; Shun Liang; Sippy Kaur; Qunrui Ye; Chunsheng Li; Li-Ping Wang; Katherine F Roby; Sandra Orsulic; Denise C Connolly; Youcheng Zhang; Kathleen Montone; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

5.  Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.

Authors:  Feng Jiang; Qi Qiu; Abha Khanna; Nevins W Todd; Janaki Deepak; Lingxiao Xing; Huijun Wang; Zhenqiu Liu; Yun Su; Sanford A Stass; Ruth L Katz
Journal:  Mol Cancer Res       Date:  2009-03-10       Impact factor: 5.852

Review 6.  ALDH1 as a functional marker of cancer stem and progenitor cells.

Authors:  Julie Douville; Raymond Beaulieu; Danuta Balicki
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

7.  Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.

Authors:  Tomonori Tanei; Koji Morimoto; Kenzo Shimazu; Seung Jin Kim; Yoshio Tanji; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

Review 8.  Treatment resistance in stem cells and breast cancer.

Authors:  Bhuvanesh Dave; Jenny Chang
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-03-04       Impact factor: 2.673

9.  Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.

Authors:  Krishna Penumatsa; Seby L Edassery; Animesh Barua; Michael J Bradaric; Judith L Luborsky
Journal:  J Ovarian Res       Date:  2010-12-22       Impact factor: 4.234

10.  ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.

Authors:  Takafumi Kuroda; Yoshihiko Hirohashi; Toshihiko Torigoe; Kazuyo Yasuda; Akari Takahashi; Hiroko Asanuma; Rena Morita; Tasuku Mariya; Takuya Asano; Masahito Mizuuchi; Tsuyoshi Saito; Noriyuki Sato
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more
  11 in total

Review 1.  Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.

Authors:  Alexander E Kudinov; John Karanicolas; Erica A Golemis; Yanis Boumber
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

Review 2.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

3.  Overexpression of Musashi-1 protein is associated with progression and poor prognosis of gastric cancer.

Authors:  Zhangxuan Shou; Xue Jin; Xujun He; Zhongsheng Zhao; Yuan Chen; Meihua Ye; Jiong Yao
Journal:  Oncol Lett       Date:  2017-03-21       Impact factor: 2.967

4.  Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: a meta-analysis.

Authors:  Wenge Zhao; Chuanxin Zang; Tingting Zhang; Jia Li; Ruijuan Liu; Fubin Feng; Qingliang Lv; Liang Zheng; Jinhui Tian; Changgang Sun
Journal:  Onco Targets Ther       Date:  2018-04-03       Impact factor: 4.147

5.  Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells.

Authors:  Qingchun Cai; Qipeng Fan; Aaron Buechlein; David Miller; Kenneth P Nephew; Sheng Liu; Jun Wan; Yan Xu
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

Review 6.  Aldehyde dehydrogenase serves as a biomarker for worse survival profiles in ovarian cancer patients: an updated meta-analysis.

Authors:  Yan Xia; Xuemin Wei; Hui Gong; Yunxiang Ni
Journal:  BMC Womens Health       Date:  2018-12-06       Impact factor: 2.809

7.  Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells.

Authors:  Maria T Löblein; Isabel Falke; Hans Theodor Eich; Burkhard Greve; Martin Götte; Fabian M Troschel
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

Review 8.  Musashi-1-A Stemness RBP for Cancer Therapy?

Authors:  Nadine Bley; Ali Hmedat; Simon Müller; Robin Rolnik; Alexander Rausch; Marcell Lederer; Stefan Hüttelmaier
Journal:  Biology (Basel)       Date:  2021-05-05

9.  Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer.

Authors:  Fabian M Troschel; Annemarie Minte; Yahia Mahmoud Ismail; Amr Kamal; Mahmoud Salah Abdullah; Sarah Hamdy Ahmed; Marie Deffner; Björn Kemper; Ludwig Kiesel; Hans Theodor Eich; Sherif Abdelaziz Ibrahim; Martin Götte; Burkhard Greve
Journal:  Int J Mol Sci       Date:  2020-03-21       Impact factor: 5.923

10.  Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma.

Authors:  Mario Cioce; Claudia Canino; Harvey Pass; Giovanni Blandino; Sabrina Strano; Vito Michele Fazio
Journal:  J Exp Clin Cancer Res       Date:  2021-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.